This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Insider Trading Alert - ARCP, COV, NYCB, CME And C Traded By Insiders

Covidien (COV) - FREE Research Report

Almeida Jose E who is President and Chief Executive at Covidien sold 17,500 shares at $66.00 on Nov. 15, 2013. Following this transaction, the President and Chief Executive owned 200,566 shares meaning that the stake was reduced by 8.03% with the 17,500 share transaction.

Lannum Coleman N III who is Vice President at Covidien sold 5,707 shares at $65.49 on Nov. 15, 2013. Following this transaction, the Vice President owned 7,374 shares meaning that the stake was reduced by 43.63% with the 5,707 share transaction.

Green Eric C who is Vice President at Covidien sold 7,392 shares at $65.00 on Nov. 15, 2013. Following this transaction, the Vice President owned 12,726 shares meaning that the stake was reduced by 36.74% with the 7,392 share transaction.

Dockendorff Charles J who is EVP & Chief Financial Officer at Covidien sold 39,397 shares at $66.22 on Nov. 15, 2013. Following this transaction, the EVP & Chief Financial Officer owned 111,273 shares meaning that the stake was reduced by 26.15% with the 39,397 share transaction.

The shares most recently traded at $67.15, up $0.93, or 1.38% since the insider transaction. Historical insider transactions for Covidien go as follows:

  • 4-Week # shares sold: 39,709
  • 12-Week # shares sold: 43,149
  • 24-Week # shares sold: 59,740

The average volume for Covidien has been 2.2 million shares per day over the past 30 days. Covidien has a market cap of $30.4 billion and is part of the health care sector and health services industry. Shares are up 14.44% year to date as of the close of trading on Friday.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The stock currently has a dividend yield of 1.96%. The company has a P/E ratio of 17.8. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on COV - FREE

TheStreet Quant Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 16,461.32 -153.49 -0.92%
S&P 500 1,927.11 -14.17 -0.73%
NASDAQ 4,382.8470 -36.6310 -0.83%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs